SALT LAKE CITY, Feb. 23 /PRNewswire-FirstCall/ -- Diabetic Treatment Centers of America, Inc. (BULLETIN BOARD: DBTC) , announced today the execution of a Letter of Intent to acquire Movement Disorder Technologies, Inc.
"Movement Disorder Technologies (MDT) has an outstanding team that has a proven history of developing significant medical devices. Providing neurologists with technology that will assist in the treatment of Parkinson's disease, Essential Tremor, and Tourette's Syndrome will dramatically increase the size of the market for Diabetic Treatment Centers of America," said Arden Oliphant, CEO of Diabetic Treatment Centers of America, Inc.
"We look forward to working with Diabetic Treatment Centers of America to leverage our technologies and provide a means to better health to those who suffer with movement disorders," said Carl L. Doane, EVP of Movement Disorder Technologies.
The Letter of Intent which was executed by both parties provides for the negotiation of the final terms, is non-binding on both parties and subject to the completion of due diligence considered normal and customary in transactions of this type.
About Diabetic Treatment Centers of America
Based in Salt Lake City, Utah, DTC of America is dedicated to providing effective medical therapies to diabetics that will significantly improve their health and well being.
Safe Harbor Statement
This news release may include forward-looking statements within the meaning of Section 27a of the United States Securities Act of 1933, as amended, and Section 21e of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.
Contact: Diabetic Treatment Centers of America, Inc. Arden Oliphant, 801-207-1816 aoliphant@dtcofamerica.com
Diabetic Treatment Centers of America, Inc.CONTACT: Arden Oliphant of Diabetic Treatment Centers of America, Inc.,+1-801-207-1816, aoliphant@dtcofamerica.com